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Abstract
Background: Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), is an ongoing pandemic that profoundly challenges healthcare systems all over the world. Fever,
cough and fatigue are the most commonly reported clinical symptoms.
Case presentation: A 58-year-old man presented at the emergency department with acute onset haemoptysis. On
the fifth day after admission, he developed massive haemoptysis. Computed tomography (CT) angiography of the
chest revealed alveolar haemorrhage, more prominent in the left lung. Flexible bronchoscopy confirmed bleeding
from the left upper lobe, confirmed by a bronchial arteriography, which was successfully embolized. Nasopharyngeal
swabs (NPS) tested for SARS-CoV-2 using real-time polymerase chain reaction (RT-PCR) repeatedly returned negative.
Surprisingly, SARS-CoV-2 was eventually detected in bronchoalveolar lavage (BAL) fluid.
Conclusions: Life-threatening haemoptysis is an unusual presentation of COVID-19, reflecting alveolar bleeding as a
rare but possible complication. This case emphasises the added value of bronchoscopy with BAL in the diagnostic
work-up in case of high clinical suspicion and negative serial NPS in patients presenting with severe symptoms.
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Background
Coronavirus disease 2019 (COVID-19) caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
an ongoing pandemic that profoundly challenges healthcare
systems all over the world. Scientific evidence on this new
virus is growing and the clinical characteristics are increas-
ingly understood. Among COVID-19 patients, fever, cough
and fatigue are the most commonly reported clinical symp-
toms. The main reason for hospitalisation is the onset of
acute hypoxemic respiratory failure [1].
Haemoptysis is rarely reported as a symptom of COVID-
19. Only very few cases have been described in literature [1,
2]. Here, we report an unusual case of a man who pre-
sented with life-threatening haemoptysis as the first and
unique symptom of COVID-19.
Case presentation
In the spring of 2020, a 58-year-old man with moderate
chronic obstructive pulmonary disease (COPD) presented
at the emergency department of the referring regional hos-
pital with moderate haemoptysis of acute onset. He re-
ported no fever, chills, chest pain or worsening dyspnoea.
A recent extensive diagnostic work-up for unintentional
weight loss was negative for cancer. The patient was a 30
pack-year current smoker. He frequently used nicotine-
containing electronic cigarettes (e-cigarettes) and had
smoked marijuana occasionally until a few months before
admission. He reported no other relevant medical history.
He worked as a librarian and lived with his wife in a rural
area. Three weeks before admission he had cleaned a
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dried-up fishpond. His medication included inhaled
formoterol, which he only used as needed, and occa-
sionally ibuprofen.
At admission the patient’s temperature was 36.2 °C,
blood pressure 163/79 mmHg, heart rate 95 beats per
minute and oxygen saturation on pulse oximetry 87% at
ambient air. He appeared comfortable, with no signs of
respiratory distress. The lungs were clear on auscultation
and the heart rhythm was regular without murmurs.
Laboratory analysis showed a normal white blood cell
count and C-reactive protein (CRP) and a haemoglobin
level of 13.2 g/dL (reference range, 13.2 to 16.8). D-dimers
were not elevated. Renal function and bilirubin were
normal, as were the levels of the liver enzymes. Anti-
neutrophil cytoplasmic antibodies (ANCAs) directed
against proteinase 3 (PR3-ANCA) and myeloperoxidase
(MPO-ANCA) were negative, as well as antibodies against
glomerular basement membrane, antinuclear and antipho-
spholipid antibodies. Arterial blood gas analysis revealed
moderate hypoxemia with a partial pressure of oxygen
(PaO2) of 60mmHg (reference range, 83–108mmHg) and
a partial pressure of carbon dioxide (PaCO2) of 37mmHg
(reference range, 35–45mmHg) resulting in an elevated al-
veolar – arterial gradient of 43.5mmHg (reference esti-
mated age-specific gradient, 17mmHg).
On computed tomography (CT) angiography of the chest,
centrally distributed ground glass opacities were seen in the
lower lobes, suggesting diffuse alveolar haemorrhage (DAH),
as well as centrilobular emphysema in the upper lobes
(Fig. 1). There was no evidence of pulmonary embolism.
According to the institutional guidelines during the current
COVID-19 pandemic, nasopharyngeal swab (NPS) samples
on two consecutive days were obtained and tested for SARS-
CoV-2 using real-time polymerase chain reaction (RT-PCR),
which repeatedly returned negative.
Flexible bronchoscopy performed on the third day re-
vealed numerous blood-tinged secretions without signs of
active bleeding. After clearing of the secretions, the bron-
chial tree appeared normal without structural abnormalities.
BAL specimens were obtained for culture and pathology.
To explore the possibility of e-cigarette or vaping product
use-associated lung injury (EVALI) and recent use of
marijuana, vitamin E acetate was tested in the BAL fluid,
but was reported negative.
Surprisingly, SARS-CoV-2 was detected in the BAL fluid
by means of RT-PCR. Based on the current insights at that
time and in accordance with the national guidelines, the
patient was started on hydroxychloroquine (400mg twice
daily at day 1, followed by 200mg twice daily at day 2 to
5) along with amoxicillin/clavulanic acid and azithromycin
(QTc 429ms before treatment initiation). Remdesivir,
tocilizumab and convalescent plasma were not available at
that time, except through clinical trials and urgent medical
need programs for which the patient did not qualify.
On day four, the patient was subsequently transferred to
the COVID-19 respiratory intermediate care unit of our
hospital. Upon admission in our centre, the patient was in
mild respiratory distress. His temperature was 38.0 °C,
blood pressure 107/67mmHg, heart rate 106 bpm and oxy-
gen saturation on pulse-oximetry 92%, while receiving sup-
plemental oxygen through a nasal cannula at a flow rate of
two litres per minute. The lungs were clear on auscultation.
Further physical examination was normal. The white blood
cell count was 6070/μL (reference range, 3650–9700/μL),
with a lymphocyte count of 730/μL (reference range, 1133–
3105/μL). The platelet count was 137,000/μL (reference
range, 149,000-319,000/μL), the hemoglobin level 10.1 g/dL
(reference range, 12.9–17.3 g/dL), the ferritin level 462 μg/L
(peak value: 608 μg/L at day 10) (reference range, 20–
280 μg/L), the total bilirubin level 2.1 g/dL (reference range,
0.2–1.3 g/dL), the aspartate aminotransferase level 335U/L
(reference range, 0–37U/L), the alanine aminotransferase
level 360 U/L (reference range, 7–40U/L) and the C-
reactive protein 12.1 g/L (reference range, < 5 g/L). Renal
function was normal, as was the coagulation screen with a
prothrombin (PT) level of 79% (reference range, 70 to 120),
an activated partial thromboplastin time (aPTT) of 36 s
(reference range, 28.9 to 38.1) and D-dimers of 880 ng/mL
(reference range < 270 ng/mL). Tests for Legionella pneu-
mophila serogroup 1 and Streptococcus pneumoniae anti-
gens in the urine were negative, as well as leptospirosis
serology. Pulmonary hypertension was ruled out by trans-
thoracic echocardiography.
On the fifth day of hospitalisation, the patient devel-
oped sudden massive haemoptysis and the oxygen satur-
ation dropped to 82% despite the patient was receiving
Fig. 1 CT showing central ground glass opacities in the lower lobes,
suggesting DAH
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15 l per minute supplemental oxygen through a non-
rebreathing mask with reservoir bag. An urgent intubation
was performed and continuous infusions of propofol, remi-
fentanil and norepinephrine were initiated. A new CT angi-
ography of the chest was done, revealing an alveolar
haemorrhage, more prominent in the left lung. Flexible
bronchoscopy performed at the intensive care unit revealed
a blood clot obstructing the left main bronchus. After ma-
nipulation and retraction of the clot, bleeding recom-
menced and appeared to initiate from the left upper lobe.
Local iced saline and epinephrine were administered. Be-
cause of persistent bleeding, a bronchial arteriography was
performed, showing an inflammatory blush arising from
the left bronchial artery and from the left branch of the
right bronchial artery, which were successfully embolized.
The patient was extubated the next day and recovered
fully. Follow up chest CT two weeks later showed complete
resolution of the ground glass opacities (Fig. 2). Given the
fact that no other aetiology was found, COVID-19 was con-
sidered to be the main cause of this patient’s haemoptysis.
Discussion and conclusions
The diagnosis of COVID-19 can sometimes be challenging
due to a nonspecific clinical presentation. Cough, fever and
fatigue are the most commonly reported clinical symptoms.
Unusually, in this case, haemoptysis was the initial and
unique symptom of SARS-CoV-2 infection in a patient with
underlying emphysema. Haemoptysis is the expectoration
of blood or blood-tinged sputum from the respiratory tract.
It is considered life-threatening when it causes clinical con-
sequences such as respiratory failure from airway obstruc-
tion, as in this case, or hypotension [3, 4]. In Europe,
bronchiectasis, malignancies, post-tuberculosis sequelae
and idiopathic bleedings have been recognised as the most
frequent causes over the last decade [5]. Other, more
rare aetiologies, are pulmonary embolism, vasculitis, co-
agulation disorders, and arteriovenous malformations
[4]. None of these were present in this patient. Since
the patient frequently used e-cigarettes, EVALI was
briefly considered but discarded when the diagnosis of
COVID-19 was established [6].
To date, haemoptysis has rarely been described as a
symptom of COVID-19. In a large case series including
1099 hospitalised patients with laboratory confirmed
COVID-19 in China, haemoptysis occurred in ten patients
(0.9%) [1]. Fu and colleagues on the other hand performed
a systematic review and meta-analysis of the clinical char-
acteristics of COVID-19 involving 43 studies and showed a
prevalence of 2% [2]. However, the severity of haemoptysis
was not mentioned. In two other case reports, haemoptysis
was described as a symptom of a SARS-CoV-2 infection.
In the case presentation of Shi et al. [7], haemoptysis was
the only clinical symptom during the first ten days of the
disease course, whereas Casey and co-workers presented a
case of COVID-19 associated with acute segmental pul-
monary emboli which eventually caused haemoptysis [8].
The latter demonstrates the highly thromboembolic risk
related with this disease [9]. It is not known whether alveo-
lar capillary microthrombi contributed to the pulmonary
haemorrhage in this patient.
To our knowledge, this is the first case of COVID-19 as-
sociated with life-threatening haemoptysis, initially thought
to be a diffuse alveolar haemorrhage (DAH). Follow-up
chest CT after two weeks showed complete resolution of
the ground glass opacities, reinforcing the hypothesis that
these opacities were caused by alveolar bleeding rather than
COVID-19 pneumonia. Other infectious diseases have been
linked with alveolar haemorrhage in immunocompetent pa-
tients including influenza A (H1N1), dengue, malaria,
Staphylococcus aureus infection and leptospirosis [10]. The
latter was explicitly ruled out in this case because of the ex-
posure history and the concomitant thrombocytopenia and
elevated hepatic transaminases.
In this case, the diagnosis of COVID-19 was established
by means of SARS-CoV-2 RT-PCR on BAL fluid whereas
two consecutive NPS were negative. A recent study
showed that BAL fluid yielded the highest positive rates
suggesting a higher sensitivity than NPS [11]. To minimize
the risk of transmission of infection to health care
workers, bronchoscopy only has a limited role in the diag-
nosis of COVID-19 [12]. However, it can have an added
value in establishing alternative microbiological diagnoses
[13]. Furthermore, in the current ongoing pandemic set-
ting, including SARS-CoV-2 PCR in every BAL specimen
obtained for diagnostic workup of unexplained pulmonary
pathology might be warranted.
Fig. 2 Follow up chest CT showing complete resolution of the
ground glass opacities
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In summary, life-threating haemoptysis can be the first
presentation of SARS-CoV-2 infection. This case illus-
trates alveolar bleeding as a possible complication of
COVID-19. In this patient, bronchoscopy with BAL had
an added diagnostic value. In patients with severe symp-
toms and of high clinical suspicion despite negative
NPS, bronchoscopy with BAL should be considered in
the diagnostic work-up. Despite all current knowledge of
COVID-19, it is still a novel disease and clinicians
should be careful when patients present with respiratory
symptoms of unknown aetiology.
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